EUVIMEDEUVIMED entdecken
Open Access

Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries

Nayan Lamba iD, Daniel N Cagney, Paul J Catalano, Hesham Elhalawani, Daphne A Haas-Kogan, Patrick Y Wen, Nikhil Wagle, Nancy U Lin, Ayal A Aizer, Shyam Tanguturi

Neuro-Oncology · 04.05.2023 · 25 (5) · 973-983

DOI: 10.1093/neuonc/noac249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 11.11.2022. Verfasst von Nayan Lamba und 9 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Meningeal Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Kiki Fund for Breast Cancer Leptomeningeal Metastases Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leptomeningeal disease (LMD) is a relatively uncommon manifestation of advanced cancer. Patients with LMD carry a poor prognosis and often decline rapidly, complicating inclusion in clinical trials. Identification of LMD subsets of greater incidence and more favorable prognosis might facilitate dedicated clinical trials in the future. We hypothesized that patients with breast cancer may represent such a population and sought to assess the relative incidence and prognosis of LMD secondary to breast vs. non-breast primaries.

Methods

We identified 2411 patients with intracranial metastases secondary to breast (N = 501) and non-breast (N = 1910) primaries at Brigham and Women’s Hospital/Dana-Farber Cancer Institute between 1996 and 2020, of whom 112 presented with and an additional 161 subsequently developed LMD. A log-rank test and Cox modeling were used to compare outcomes in patients with breast vs. non-breast primaries.

Results

Among patients with newly diagnosed intracranial disease, the incidence proportion of concurrent LMD was 11.4% vs. 2.9% among patients with breast vs. non-breast primaries (P < .001). Development of LMD among initially LMD-naïve patients was also more common among patients with breast vs. non-breast primaries (HR = 1.49 [1.05–2.11], P = .03). Patients with LMD secondary to breast vs. non-breast primaries displayed lower all-cause mortality (HR 0.70 [0.52–0.93], P = .01; median survival: 5.2 vs. 2.4 months, respectively), with a greater numerical difference observed in patients with LMD at intracranial involvement (7.4 vs. 2.6 months, respectively).

Conclusions

Patients with breast cancer and LMD may represent an ideal population for clinical trials given the higher incidence and potentially more favorable prognosis seen in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMeningeal NeoplasmsBrain NeoplasmsHumansFemaleIncidencePrognosisRetrospective Studies

Stichwörter der Autor:innen

brain metastasesbreast cancerleptomeningeal disease

Autor:innen und Institutionen

  • Harvard Radiation Oncology Program, Harvard University, Boston, Massachusetts, USA.
  • Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Mater Private Hospital, Dublin, Ireland.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Center for Neuro-Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Nayan Lamba

Förderung

  • Kiki Fund for Breast Cancer Leptomeningeal Metastases Research

Zitieren

APA

Lamba, N., Cagney, D. N., Catalano, P. J., Elhalawani, H., Haas-Kogan, D. A., Wen, P. Y., Wagle, N., Lin, N. U., Aizer, A. A., & Tanguturi, S. (2023). Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro-Oncology, 25(5), 973-983. https://doi.org/10.1093/neuonc/noac249

Vancouver

Lamba N, Cagney DN, Catalano PJ, Elhalawani H, Haas-Kogan DA, Wen PY, et al. Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries. Neuro-Oncology. 2023;25(5):973-983. doi:10.1093/neuonc/noac249

BibTeX
@article{Lamba2023,
  author = {Lamba, Nayan and Cagney, Daniel N and Catalano, Paul J and Elhalawani, Hesham and Haas-Kogan, Daphne A and Wen, Patrick Y and Wagle, Nikhil and Lin, Nancy U and Aizer, Ayal A and Tanguturi, Shyam},
  title = {Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries},
  journal = {Neuro-Oncology},
  year = {2023},
  volume = {25},
  number = {5},
  pages = {973--983},
  doi = {10.1093/neuonc/noac249}
}
Kostenlos starten →